Advancing the development of interchangeable biosimilars and reducing or developing alternatives to clinical studies involving human subjects have been highlighted as the key priorities for a US Food and Drug Administration regulatory science pilot program under the third iteration of the Biosimilar User Fee Amendments, in a detailed new document released by the agency.
In the “Research Roadmap” document that has